Beam Therapeutics discusses Q3 results and ASH abstracts on investor call

Beam Therapeutics Inc.

2024-Q3 EPS reported -$3.49 revenue$33,451,000

Investor presentation covered Q3 financial results, but no specific figures provided in filing.
Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.
Company reiterated sickle cell disease strategy and provided business update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.